Marianne De Backer, CEO of Vir Biotechnology, Inc., recently sold 72,559 shares in an open-market transaction, as disclosed in an SEC Form 4 filing. The shares were sold at $9.16 each, reflecting a notable increase in the stock’s value, which has appreciated nearly 80% over the past year. This sale reduced De Backer’s direct ownership by 6.76%, leaving her with 948,145 shares.
This transaction aligns with De Backer’s historical selling pattern, where her average recent sales have been around 60,000 shares. Importantly, the sale did not involve any derivative securities or options, suggesting it was a straightforward liquidation of common stock. Despite the sale, De Backer retains over 90% of her holdings, indicating confidence in the company’s future.
For investors, this sale appears more like a personal liquidity event rather than a signal of distress. With promising clinical trial results for VIR-5500 and a significant partnership with Astellas Pharma, Vir Biotechnology is positioned for potential growth, making it a company to watch in the infectious disease therapeutics sector.
Source: fool.com